Sarilumab vs tocilizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: IL-6 receptor · full Rheumatoid Arthritis pipeline

Sarilumab

Marketed by Sanofi and partners

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT01061736 · Phase 2/3 · completed

This was a large, randomized, triple-blind, placebo-controlled trial with adequate sample size and hard clinical/functional/radiographic primary endpoints (ACR20 response, HAQ-DI, and van der Heijde-modified Total Sharp Score). In the confirmatory Part B, both sarilumab 150 mg and 200 mg every 2 weeks met all three primary endpoints with highly significant differences from placebo (p<0.0001), and Part A also showed significant ACR20 responses for several sarilumab doses. The positive, well-designed confirmatory results support strong evidence for sarilumab.

Next expected readout: March 2028 · NCT03414502 (registry estimate)

Reported efficacy

DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106) (met)

Result source: NCT02332590

tocilizumab · Actemra / RoActemra

Marketed by Roche and partners

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT03155347 · Phase 3 · completed

This randomized, double-blind, active-comparator trial of 340 participants met its primary endpoint: about half of tocilizumab-treated patients achieved an ACR20 response at 24 weeks, compared with a quarter on methotrexate alone, a highly statistically significant difference for both the combination and monotherapy arms.

Next expected readout: August 2028 · NCT05869955 (registry estimate)

Reported efficacy

Percentage of Participants With an American College of Rheumatology (ACR) 20 (ACR20) Response at Week 24: ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001 (met)

Result source: NCT03155347

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSarilumabtocilizumab
ACR2066.4% vs 33.4%+33 vs placebo200 mg q2w · wk 24 · n 399NCT01061736
11 other results
  • 60.9% vs 33.7% 200 mg q2w · wk 24 · n 184 · Phase 3 · primary NCT01709578
  • 58% vs 33.4% 150 mg q2w · wk 24 · n 400 · Phase 2/3 · primary NCT01061736
  • 57.5% vs 14.8% 200 mg · wk 24 · n 80 · Phase 3 · primary NCT02293902
  • 55.8% vs 33.7% 150 mg q2w · wk 24 · n 181 · Phase 3 · primary NCT01709578
  • 65.4% vs 46.2% 200 mg q2w · wk 12 · n 52 · Phase 2/3 · primary NCT01061736
  • 67.9% vs 14.8% 150 mg · wk 24 · n 81 · Phase 3 · primary NCT02293902
  • 72% vs 46.2% 150 mg qw · wk 12 · n 50 · Phase 2/3 · primary NCT01061736
  • 66.7% vs 46.2% 150 mg q2w · wk 12 · n 51 · Phase 2/3 · primary NCT01061736
  • 62% vs 46.2% 100 mg qw · wk 12 · n 50 · Phase 2/3 · primary NCT01061736
  • 49% vs 46.2% 100 mg q2w · wk 12 · n 51 · Phase 2/3 · primary NCT01061736
  • 71.7% vs 58.4% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590
60.9% vs 31.5%+29.4 vs placebo162 mg sc · wk 24 · n 437NCT01232569
8 other results
  • 56.3% vs 27% 8 mg/kg · wk 24 · n 398 · Phase 3 · primary NCT00106535
  • 50.6% vs 27% 4 mg/kg · wk 24 · n 399 · Phase 3 · primary NCT00106535
  • 55.8% vs 24.7% 8 mg/kg · wk 52 · n 398 · Phase 3 · secondary NCT00106535
  • 54.5% vs 29.3% 8 mg/kg · wk 104 · n 398 · Phase 3 · secondary NCT00106535
  • 47.9% vs 24.7% 4 mg/kg · wk 52 · n 399 · Phase 3 · secondary NCT00106535
  • 49.1% vs 29.3% 4 mg/kg · wk 104 · n 399 · Phase 3 · secondary NCT00106535
  • 52.9% vs 25% wk 24 · Phase 3 · primary NCT03155347
  • 50% vs 25% wk 24 · Phase 3 · primary NCT03155347
ACR5040.8% vs 18.2%+22.6 vs placebo200 mg q2w · wk 24 · n 184NCT01709578
2 other results
  • 37% vs 18.2% 150 mg q2w · wk 24 · n 181 · Phase 3 · secondary NCT01709578
  • 45.7% vs 29.7% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590
32.2% vs 9.7%+22.5 vs placebo8 mg/kg · wk 24 · n 398NCT00106535
5 other results
  • 36.4% vs 10.2% 8 mg/kg · wk 52 · n 398 · Phase 3 · secondary NCT00106535
  • 38.9% vs 19.8% 8 mg/kg · wk 104 · n 398 · Phase 3 · secondary NCT00106535
  • 25.1% vs 9.7% 4 mg/kg · wk 24 · n 399 · Phase 3 · secondary NCT00106535
  • 30.3% vs 10.2% 4 mg/kg · wk 52 · n 399 · Phase 3 · secondary NCT00106535
  • 37.6% vs 19.8% 4 mg/kg · wk 104 · n 399 · Phase 3 · secondary NCT00106535
ACR7016.3% vs 7.2%+9.1 vs placebo200 mg q2w · wk 24 · n 184NCT01709578
2 other results
  • 19.9% vs 7.2% 150 mg q2w · wk 24 · n 181 · Phase 3 · secondary NCT01709578
  • 23.4% vs 11.9% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590
12.6% vs 2%+10.6 vs placebo8 mg/kg · wk 24 · n 398NCT00106535
5 other results
  • 20.1% vs 3.8% 8 mg/kg · wk 52 · n 398 · Phase 3 · secondary NCT00106535
  • 22.4% vs 12.2% 8 mg/kg · wk 104 · n 398 · Phase 3 · secondary NCT00106535
  • 11% vs 2% 4 mg/kg · wk 24 · n 399 · Phase 3 · secondary NCT00106535
  • 16.5% vs 3.8% 4 mg/kg · wk 52 · n 399 · Phase 3 · secondary NCT00106535
  • 24.3% vs 12.2% 4 mg/kg · wk 104 · n 399 · Phase 3 · secondary NCT00106535
DAS28-CRP remission28.8% vs 7.2%+21.6 vs placebo200 mg q2w · wk 24 · n 184NCT01709578
4 other results
  • 17.9% vs 3.9% 200 mg q2w · wk 12 · n 184 · Phase 3 · secondary NCT01709578
  • 24.9% vs 7.2% 150 mg q2w · wk 24 · n 181 · Phase 3 · secondary NCT01709578
  • 17.1% vs 3.9% 150 mg q2w · wk 12 · n 181 · Phase 3 · secondary NCT01709578
  • 34.2% vs 13.5% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590
—Not posted · NCT00106548
HAQ-DI, change-0.5 vs -0.3−0.2 vs placebo200 mg q2w · wk 12 · n 171NCT01709578
4 other results
  • -0.5 vs -0.3 150 mg q2w · wk 12 · n 165 · Phase 3 · primary NCT01709578
  • -0.6 vs -0.3 200 mg q2w · wk 24 · n 136 · Phase 3 · secondary NCT01709578
  • -0.5 vs -0.3 150 mg q2w · wk 24 · n 127 · Phase 3 · secondary NCT01709578
  • -0.6 vs -0.4 200 mg · wk 24 · n 165 · Phase 3 · secondary NCT02332590
-0.5 vs -0.3−0.2 vs placebo162 mg sc · wk 24 · n 348NCT01232569
6 other results
  • -0.5 vs -0.3 8 mg/kg · wk 24 · n 398 · Phase 3 · secondary NCT00106535
  • -0.6 vs -0.4 8 mg/kg · wk 52 · n 263 · Phase 3 · secondary NCT00106535
  • -0.6 vs -0.5 8 mg/kg · wk 104 · n 231 · Phase 3 · secondary NCT00106535
  • -0.5 vs -0.3 4 mg/kg · wk 24 · n 399 · Phase 3 · secondary NCT00106535
  • -0.5 vs -0.4 4 mg/kg · wk 52 · n 235 · Phase 3 · secondary NCT00106535
  • -0.6 vs -0.5 4 mg/kg · wk 104 · n 218 · Phase 3 · secondary NCT00106535
Modified Sharp score, change—Trial running · NCT034145020.4 vs 2.0−1.6 vs placebo8 mg/kg · wk 104 · n 353NCT00106535
8 other results
  • 0.3 vs 1.1 8 mg/kg · wk 52 · n 348 · Phase 3 · primary NCT00106535
  • 0.6 vs 2.0 4 mg/kg · wk 104 · n 343 · Phase 3 · primary NCT00106535
  • 0.3 vs 1.1 4 mg/kg · wk 52 · n 339 · Phase 3 · primary NCT00106535
  • 0.6 vs 1.2 162 mg sc · wk 24 · n 391 · Phase 3 · secondary NCT01232569
  • 0.3 vs 1.6 8 mg/kg · wk 80 · n 353 · Phase 3 · secondary NCT00106535
  • 0.2 vs 0.5 8 mg/kg · wk 24 · n 334 · Phase 3 · secondary NCT00106535
  • 0.5 vs 1.6 4 mg/kg · wk 80 · n 343 · Phase 3 · secondary NCT00106535
  • 0.2 vs 0.5 4 mg/kg · wk 24 · n 327 · Phase 3 · secondary NCT00106535

ACR20

Sarilumab
66.4% vs 33.4%+33 vs placebo200 mg q2w · wk 24 · n 399NCT01061736
11 other results
  • 60.9% vs 33.7% 200 mg q2w · wk 24 · n 184 · Phase 3 · primary NCT01709578
  • 58% vs 33.4% 150 mg q2w · wk 24 · n 400 · Phase 2/3 · primary NCT01061736
  • 57.5% vs 14.8% 200 mg · wk 24 · n 80 · Phase 3 · primary NCT02293902
  • 55.8% vs 33.7% 150 mg q2w · wk 24 · n 181 · Phase 3 · primary NCT01709578
  • 65.4% vs 46.2% 200 mg q2w · wk 12 · n 52 · Phase 2/3 · primary NCT01061736
  • 67.9% vs 14.8% 150 mg · wk 24 · n 81 · Phase 3 · primary NCT02293902
  • 72% vs 46.2% 150 mg qw · wk 12 · n 50 · Phase 2/3 · primary NCT01061736
  • 66.7% vs 46.2% 150 mg q2w · wk 12 · n 51 · Phase 2/3 · primary NCT01061736
  • 62% vs 46.2% 100 mg qw · wk 12 · n 50 · Phase 2/3 · primary NCT01061736
  • 49% vs 46.2% 100 mg q2w · wk 12 · n 51 · Phase 2/3 · primary NCT01061736
  • 71.7% vs 58.4% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590
tocilizumab
60.9% vs 31.5%+29.4 vs placebo162 mg sc · wk 24 · n 437NCT01232569
8 other results
  • 56.3% vs 27% 8 mg/kg · wk 24 · n 398 · Phase 3 · primary NCT00106535
  • 50.6% vs 27% 4 mg/kg · wk 24 · n 399 · Phase 3 · primary NCT00106535
  • 55.8% vs 24.7% 8 mg/kg · wk 52 · n 398 · Phase 3 · secondary NCT00106535
  • 54.5% vs 29.3% 8 mg/kg · wk 104 · n 398 · Phase 3 · secondary NCT00106535
  • 47.9% vs 24.7% 4 mg/kg · wk 52 · n 399 · Phase 3 · secondary NCT00106535
  • 49.1% vs 29.3% 4 mg/kg · wk 104 · n 399 · Phase 3 · secondary NCT00106535
  • 52.9% vs 25% wk 24 · Phase 3 · primary NCT03155347
  • 50% vs 25% wk 24 · Phase 3 · primary NCT03155347

ACR50

Sarilumab
40.8% vs 18.2%+22.6 vs placebo200 mg q2w · wk 24 · n 184NCT01709578
2 other results
  • 37% vs 18.2% 150 mg q2w · wk 24 · n 181 · Phase 3 · secondary NCT01709578
  • 45.7% vs 29.7% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590
tocilizumab
32.2% vs 9.7%+22.5 vs placebo8 mg/kg · wk 24 · n 398NCT00106535
5 other results
  • 36.4% vs 10.2% 8 mg/kg · wk 52 · n 398 · Phase 3 · secondary NCT00106535
  • 38.9% vs 19.8% 8 mg/kg · wk 104 · n 398 · Phase 3 · secondary NCT00106535
  • 25.1% vs 9.7% 4 mg/kg · wk 24 · n 399 · Phase 3 · secondary NCT00106535
  • 30.3% vs 10.2% 4 mg/kg · wk 52 · n 399 · Phase 3 · secondary NCT00106535
  • 37.6% vs 19.8% 4 mg/kg · wk 104 · n 399 · Phase 3 · secondary NCT00106535

ACR70

Sarilumab
16.3% vs 7.2%+9.1 vs placebo200 mg q2w · wk 24 · n 184NCT01709578
2 other results
  • 19.9% vs 7.2% 150 mg q2w · wk 24 · n 181 · Phase 3 · secondary NCT01709578
  • 23.4% vs 11.9% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590
tocilizumab
12.6% vs 2%+10.6 vs placebo8 mg/kg · wk 24 · n 398NCT00106535
5 other results
  • 20.1% vs 3.8% 8 mg/kg · wk 52 · n 398 · Phase 3 · secondary NCT00106535
  • 22.4% vs 12.2% 8 mg/kg · wk 104 · n 398 · Phase 3 · secondary NCT00106535
  • 11% vs 2% 4 mg/kg · wk 24 · n 399 · Phase 3 · secondary NCT00106535
  • 16.5% vs 3.8% 4 mg/kg · wk 52 · n 399 · Phase 3 · secondary NCT00106535
  • 24.3% vs 12.2% 4 mg/kg · wk 104 · n 399 · Phase 3 · secondary NCT00106535

DAS28-CRP remission

Sarilumab
28.8% vs 7.2%+21.6 vs placebo200 mg q2w · wk 24 · n 184NCT01709578
4 other results
  • 17.9% vs 3.9% 200 mg q2w · wk 12 · n 184 · Phase 3 · secondary NCT01709578
  • 24.9% vs 7.2% 150 mg q2w · wk 24 · n 181 · Phase 3 · secondary NCT01709578
  • 17.1% vs 3.9% 150 mg q2w · wk 12 · n 181 · Phase 3 · secondary NCT01709578
  • 34.2% vs 13.5% 200 mg · wk 24 · n 184 · Phase 3 · secondary NCT02332590
tocilizumab
—Not posted · NCT00106548

HAQ-DI, change

Sarilumab
-0.5 vs -0.3−0.2 vs placebo200 mg q2w · wk 12 · n 171NCT01709578
4 other results
  • -0.5 vs -0.3 150 mg q2w · wk 12 · n 165 · Phase 3 · primary NCT01709578
  • -0.6 vs -0.3 200 mg q2w · wk 24 · n 136 · Phase 3 · secondary NCT01709578
  • -0.5 vs -0.3 150 mg q2w · wk 24 · n 127 · Phase 3 · secondary NCT01709578
  • -0.6 vs -0.4 200 mg · wk 24 · n 165 · Phase 3 · secondary NCT02332590
tocilizumab
-0.5 vs -0.3−0.2 vs placebo162 mg sc · wk 24 · n 348NCT01232569
6 other results
  • -0.5 vs -0.3 8 mg/kg · wk 24 · n 398 · Phase 3 · secondary NCT00106535
  • -0.6 vs -0.4 8 mg/kg · wk 52 · n 263 · Phase 3 · secondary NCT00106535
  • -0.6 vs -0.5 8 mg/kg · wk 104 · n 231 · Phase 3 · secondary NCT00106535
  • -0.5 vs -0.3 4 mg/kg · wk 24 · n 399 · Phase 3 · secondary NCT00106535
  • -0.5 vs -0.4 4 mg/kg · wk 52 · n 235 · Phase 3 · secondary NCT00106535
  • -0.6 vs -0.5 4 mg/kg · wk 104 · n 218 · Phase 3 · secondary NCT00106535

Modified Sharp score, change

Sarilumab
—Trial running · NCT03414502
tocilizumab
0.4 vs 2.0−1.6 vs placebo8 mg/kg · wk 104 · n 353NCT00106535
8 other results
  • 0.3 vs 1.1 8 mg/kg · wk 52 · n 348 · Phase 3 · primary NCT00106535
  • 0.6 vs 2.0 4 mg/kg · wk 104 · n 343 · Phase 3 · primary NCT00106535
  • 0.3 vs 1.1 4 mg/kg · wk 52 · n 339 · Phase 3 · primary NCT00106535
  • 0.6 vs 1.2 162 mg sc · wk 24 · n 391 · Phase 3 · secondary NCT01232569
  • 0.3 vs 1.6 8 mg/kg · wk 80 · n 353 · Phase 3 · secondary NCT00106535
  • 0.2 vs 0.5 8 mg/kg · wk 24 · n 334 · Phase 3 · secondary NCT00106535
  • 0.5 vs 1.6 4 mg/kg · wk 80 · n 343 · Phase 3 · secondary NCT00106535
  • 0.2 vs 0.5 4 mg/kg · wk 24 · n 327 · Phase 3 · secondary NCT00106535
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
20 other shared endpoints and safety

Coverage. Sarilumab: 24 of 24 rows · tocilizumab: 24 of 24 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSarilumab
Rows use multiple source trials
tocilizumab
Rows use multiple source trials
ACR20
responder rate · % of participants
No placebo or comparator arm
82.9% (n=1898) @ 48wka,b
NCT01146652 · Phase 3 · combination
show 1 more dose
85% (n=111) @ 48wk
NCT01146652 · Phase 3 · monotherapy
13.5% (n=96) @ 48wk*b
NCT01941095 · Phase 3 · other · converted to % from 13 participants as posted
2 other source trials
62.1% (n=140) @ 48wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 87 participants as posted
57.1% (n=21) @ 48wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 12 participants as posted
ACR20
responder rate · % of participants
No placebo or comparator arm
ACR20
40% (n=15) @ 52wk200 mg q2wa,b,c,d
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
73.3% (n=15) @ 52wk150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
69.7% (n=33) @ 24wkb,c,d
ACR20
NCT02001987 · Phase 3 · registry result, not featured evidence
2 other source trials
91.49% (n=52) @ 24wk
ACR20
NCT01951170 · Phase 3 · registry result, not featured evidence
62.4% (n=85) @ 24wk
ACR20
NCT01988012 · Phase 3 · registry result, not featured evidence
ACR50
responder rate · % of participants
No placebo or comparator arm
62.4% (n=1897) @ 48wka,b
NCT01146652 · Phase 3 · combination
show 1 more dose
69.2% (n=111) @ 48wk
NCT01146652 · Phase 3 · monotherapy
52.1% (n=140) @ 48wk*a,b
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 73 participants as posted
show 1 more dose
52.4% (n=21) @ 48wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 11 participants as posted
ACR50
responder rate · % of participants
No placebo or comparator arm
ACR50
33.3% (n=15) @ 52wk200 mg q2wa,b,c,d
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
60% (n=15) @ 52wk150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
54.5% (n=33) @ 24wkb,c,d
ACR50
NCT02001987 · Phase 3 · registry result, not featured evidence
2 other source trials
76.6% (n=52) @ 24wk
ACR50
NCT01951170 · Phase 3 · registry result, not featured evidence
37.6% (n=85) @ 24wk
ACR50
NCT01988012 · Phase 3 · registry result, not featured evidence
ACR70
responder rate · % of participants
No placebo or comparator arm
40.6% (n=1901) @ 48wka,b
NCT01146652 · Phase 3 · combination
show 1 more dose
43.8% (n=111) @ 48wk
NCT01146652 · Phase 3 · monotherapy
40% (n=140) @ 48wk*a,b
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 56 participants as posted
show 1 more dose
38.1% (n=21) @ 48wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 8 participants as posted
ACR70
responder rate · % of participants
No placebo or comparator arm
ACR70
26.7% (n=15) @ 52wk200 mg q2wa,b,c,d
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
53.3% (n=15) @ 52wk150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
33.3% (n=33) @ 24wkb,c,d
ACR70
NCT02001987 · Phase 3 · registry result, not featured evidence
2 other source trials
53.19% (n=52) @ 24wk
ACR70
NCT01951170 · Phase 3 · registry result, not featured evidence
20% (n=85) @ 24wk
ACR70
NCT01988012 · Phase 3 · registry result, not featured evidence
CDAI
absolute change · score
No placebo or comparator arm
-14.6 score @ 24wkb,c
NCT03449758 · Phase 4 · registry result, not featured evidence
0.321 score @ 24wka,b,c
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
2.663 score @ 24wk
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
DAS28 Remission
responder rate · % of participants
No placebo or comparator arm
57% (n=1873) @ 96wka,e,b
NCT01146652 · Phase 3 · combination
show 1 more dose
71.7% (n=110) @ 96wk
NCT01146652 · Phase 3 · monotherapy
45.8% (n=115) @ 96wke,b
NCT01149057 · Phase 4 · registry result, not featured evidence
1 other source trial
41.2% (n=68)
NCT01219933 · Phase 4 · registry result, not featured evidence
DAS28-ESR
absolute change · score
-3.28 vs -2.2 Adalimumab score @ 24wk200 mgb,f
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-3.28 vs -1.49 placebo score @ 24wk8 mg/kga,b,f
NCT00106535 · Phase 3 · combination
show 1 more dose
-2.45 vs -1.49 placebo score @ 24wk4 mg/kg
NCT00106535 · Phase 3 · combination
DAS28-ESR
absolute change · score
No placebo or comparator arm
-2.7 score @ 24wkg,b,c
NCT03449758 · Phase 4 · registry result, not featured evidence
-3.14 score @ 24wkg,b,c
NCT01941095 · Phase 3 · other
15 other source trials
-3.24 score @ 24wk
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-3.21 score @ 24wk
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
-0.075 score @ 24wk
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
0.538 score @ 24wk
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
-3.3 score @ 24wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-3.33 score @ 24wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-1.63 score
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-3.28 score @ 24wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-2.88 score
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-3.2 score @ 24wk
NCT01941940 · Phase 3 · registry result, not featured evidence
3.232 score @ 24wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-3.3 score @ 24wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-3.07 score @ 24wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-3.01 score @ 24wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-2.47 score @ 24wk
NCT01988012 · Phase 3 · registry result, not featured evidence
FACIT-Fatigue
absolute change · score
10.18 vs 8.41 Adalimumab score @ 24wk200 mgb,f
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
2 other source trials
9.86 vs 6.82 placebo score @ 24wk150 mg q2w
NCT01709578 · Phase 3
10.06 vs 6.82 placebo score @ 24wk200 mg q2w
NCT01709578 · Phase 3
6.91 vs 5.32 placebo score @ 24wk8 mg/kga,b,f
NCT00106535 · Phase 3 · combination
show 1 more dose
7.14 vs 5.32 placebo score @ 24wk4 mg/kg
NCT00106535 · Phase 3 · combination
FACIT-Fatigue
absolute change · score
No placebo or comparator arm
11.09 score @ 96wke,b,c
NCT01146652 · Phase 3 · combination
7.3 score @ 96wka,e,b,c
NCT01149057 · Phase 4 · registry result, not featured evidence
show 1 more dose
7.3 score @ 96wk
NCT01149057 · Phase 4 · registry result, not featured evidence
HAQ-DI
absolute change · score
No placebo or comparator arm
-0.72 score @ 96wka,e,b
NCT01146652 · Phase 3 · combination
show 1 more dose
-0.69 score @ 96wk
NCT01146652 · Phase 3 · monotherapy
-0.5 score @ 96wke,b
NCT01149057 · Phase 4 · registry result, not featured evidence
HAQ-DI
absolute value · score
No placebo or comparator arm
0.8 score @ 24wkb,c
NCT03449758 · Phase 4 · registry result, not featured evidence
0.551 score @ 24wk8 mg/kgb,c
NCT01089023 · Phase 4 · registry result, not featured evidence
5 other source trials
0.84 score @ 24wk
NCT00996203 · Phase 4 · registry result, not featured evidence
1.16 score @ 24wk8 mg/kg
NCT01010503 · Phase 4 · registry result, not featured evidence
1.261 score @ 24wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
1.33 score @ 24wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
0.6681 score @ 24wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
Modified Sharp
absolute change · score
No placebo or comparator arm
2.83 score @ 192wkb,c,h
NCT01146652 · Phase 3 · combination
0 score @ 24wkb,c,h
NCT01951170 · Phase 3 · registry result, not featured evidence
Pain VAS
absolute change · mm
No placebo or comparator arm
-38.46 mm @ 60wka,b
NCT01146652 · Phase 3 · combination
show 1 more dose
-40.79 mm @ 60wk
NCT01146652 · Phase 3 · monotherapy
-42 mm @ 60wkb
NCT02001987 · Phase 3 · registry result, not featured evidence
Patient Global VAS
absolute change · mm
No placebo or comparator arm
-36.91 mm @ 24wka,b
NCT01146652 · Phase 3 · combination
show 1 more dose
-36.12 mm @ 24wk
NCT01146652 · Phase 3 · monotherapy
-34.3 mm @ 24wkb
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
3 other source trials
-28.4 mm @ 24wk
NCT01941940 · Phase 3 · registry result, not featured evidence
19 mm @ 24wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
16.63 mm @ 24wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
Patient Global VAS
absolute value · mm
No placebo or comparator arm
34.6 mm @ 24wkg,b
NCT03449758 · Phase 4 · registry result, not featured evidence
26.6 mm @ 24wka,g,b
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
23.8 mm @ 24wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
Physician Global VAS
absolute change · mm
No placebo or comparator arm
-48.39 mm @ 24wka,b
NCT01146652 · Phase 3 · combination
show 1 more dose
-50.82 mm @ 24wk
NCT01146652 · Phase 3 · monotherapy
-38 mm @ 24wkb
NCT01941940 · Phase 3 · registry result, not featured evidence
RAID
absolute change · score
No placebo or comparator arm
-2.4 score @ 24wkb,c
NCT03449758 · Phase 4 · registry result, not featured evidence
-0.22 score @ 24wka,b,c
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
show 1 more dose
0.469 score @ 24wk
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
Dropout rate
13.5%200 mg q2wi
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
show 35 more results
—200 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
5.9%150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
8%150 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—150 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
11.8%100 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
26%100 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—100 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—100 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
49.7%Sarilumab + Disease Modifying Anti
NCT01146652 · Phase 3 · combination
40.5%Sarilumab Monotherapy
NCT01146652 · Phase 3 · monotherapy
—200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
10.3%200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
27.7%200 mg q2w
NCT01709578 · Phase 3
30.9%150 mg q2w
NCT01709578 · Phase 3
22.6%
NCT03449758 · Phase 4 · registry result, not featured evidence
—200 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
—150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
40%200 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
13.3%150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
12.5%200 mg
NCT02293902 · Phase 3 · registry result, not featured evidence
8.6%150 mg
NCT02293902 · Phase 3 · registry result, not featured evidence
—Sarilumab Rescue
NCT02293902 · Phase 3 · registry result, not featured evidence
13.5%200 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
3.6%200 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
7.1%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
5.7%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
13.4%200 mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
—200mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
10.8%150 mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
—150mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
23.5%200 mg q2w
NCT01768572 · Phase 3 · registry result, not featured evidence
18.4%150 mg q2w
NCT01768572 · Phase 3 · registry result, not featured evidence
57.7%Tocilizumabj
NCT01941095 · Phase 3 · other
show 49 more results
—Tocilizumab + Methotrexate or Othe
NCT01941095 · Phase 3 · combination
—Tocilizumab Monotherapy
NCT01941095 · Phase 3 · monotherapy
19.3%
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—8 mg/kg
NCT00106535 · Phase 3 · combination
22.7%8 mg/kg
NCT00106535 · Phase 3 · combination
—4 mg/kg
NCT00106535 · Phase 3 · combination
22.9%4 mg/kg
NCT00106535 · Phase 3 · combination
10.6%Tocilizumab IV
NCT01194414 · Phase 3
—Tocilizumab IV Then Tocilizumab SC
NCT01194414 · Phase 3
9.4%Tocilizumab SC
NCT01194414 · Phase 3
—Tocilizumab SC Then Tocilizumab IV
NCT01194414 · Phase 3
—Tocilizumab Pre-filled Syringe
NCT01232569 · Phase 3
—Tocilizumab Pre-filled Syringe to
NCT01232569 · Phase 3
3.6%
NCT01331837 · Phase 4
11.7%Tocilizumab+Prednisone (Constant D
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
11.5%Tocilizumab+Prednisone (Tapering D
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
18.5%
NCT01717859 · Phase 4 · registry result, not featured evidence
3.8%
NCT01715831 · Phase 4 · registry result, not featured evidence
39.3%
NCT01149057 · Phase 4 · registry result, not featured evidence
—TCZ + MTX (Not Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + MTX (Post-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + MTX (Pre-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
3.6%TCZ + MTX (Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + Placebo (Post-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence
—TCZ + Placebo (Pre-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence
4.9%TCZ + Placebo (Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence
55.9%
NCT01219933 · Phase 4 · registry result, not featured evidence
18.3%
NCT01163747 · Phase 4 · registry result, not featured evidence · combination
—8 mg/kg
NCT01195272 · Phase 4 · registry result, not featured evidence
14.7%8 mg/kg
NCT01119859 · Phase 4 · registry result, not featured evidence
—
NCT01089023 · Phase 4 · registry result, not featured evidence
—8 mg/kg
NCT01034397 · Phase 4 · registry result, not featured evidence
3.5%
NCT00996203 · Phase 4 · registry result, not featured evidence
—
NCT02010216 · Phase 4 · registry result, not featured evidence
—8 mg/kg
NCT01010503 · Phase 4 · registry result, not featured evidence
14.3%
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
68.2%Tocilizumab Monotherapy
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
53.6%Tocilizumab in Combination With Me
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
14.5%
NCT01941940 · Phase 3 · registry result, not featured evidence
11.3%
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
17.4%
NCT01668966 · Phase 3 · registry result, not featured evidence
14.1%Phase 1: Combination Therapy
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
13.5%Phase 1: Tocilizumab Monotherapy
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
16.5%TCZ - All Participants
NCT02001987 · Phase 3 · registry result, not featured evidence
—TCZ MONO - All Participants
NCT02001987 · Phase 3 · registry result, not featured evidence
18.2%
NCT01734993 · Phase 3 · registry result, not featured evidence
1.9%
NCT01951170 · Phase 3 · registry result, not featured evidence
20%
NCT01655381 · Phase 3 · registry result, not featured evidence
15%
NCT01988012 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
7.7%200 mg q2wi
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
show 35 more results
—200 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
3.9%150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
2%150 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—150 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
5.9%100 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
26%100 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—100 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
—100 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
26.5%Sarilumab + Disease Modifying Anti
NCT01146652 · Phase 3 · combination
13.5%Sarilumab Monotherapy
NCT01146652 · Phase 3 · monotherapy
—200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
6%200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
9.2%200 mg q2w
NCT01709578 · Phase 3
9.9%150 mg q2w
NCT01709578 · Phase 3
10.7%
NCT03449758 · Phase 4 · registry result, not featured evidence
—200 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
—150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
33.3%200 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
13.3%150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
10%200 mg
NCT02293902 · Phase 3 · registry result, not featured evidence
7.4%150 mg
NCT02293902 · Phase 3 · registry result, not featured evidence
—Sarilumab Rescue
NCT02293902 · Phase 3 · registry result, not featured evidence
11.5%200 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
1.8%200 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
5.4%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
3.8%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
10.4%200 mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
—200mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
7.7%150 mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
—150mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
17.6%200 mg q2w
NCT01768572 · Phase 3 · registry result, not featured evidence
16.3%150 mg q2w
NCT01768572 · Phase 3 · registry result, not featured evidence
11.3%Tocilizumabj
NCT01941095 · Phase 3 · other
show 49 more results
—Tocilizumab + Methotrexate or Othe
NCT01941095 · Phase 3 · combination
—Tocilizumab Monotherapy
NCT01941095 · Phase 3 · monotherapy
10.5%
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—8 mg/kg
NCT00106535 · Phase 3 · combination
—8 mg/kg
NCT00106535 · Phase 3 · combination
—4 mg/kg
NCT00106535 · Phase 3 · combination
—4 mg/kg
NCT00106535 · Phase 3 · combination
6.3%Tocilizumab IV
NCT01194414 · Phase 3
—Tocilizumab IV Then Tocilizumab SC
NCT01194414 · Phase 3
4.4%Tocilizumab SC
NCT01194414 · Phase 3
—Tocilizumab SC Then Tocilizumab IV
NCT01194414 · Phase 3
—Tocilizumab Pre-filled Syringe
NCT01232569 · Phase 3
—Tocilizumab Pre-filled Syringe to
NCT01232569 · Phase 3
—
NCT01331837 · Phase 4
3.9%Tocilizumab+Prednisone (Constant D
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
3.8%Tocilizumab+Prednisone (Tapering D
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
9.3%
NCT01717859 · Phase 4 · registry result, not featured evidence
3.8%
NCT01715831 · Phase 4 · registry result, not featured evidence
9%
NCT01149057 · Phase 4 · registry result, not featured evidence
—TCZ + MTX (Not Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + MTX (Post-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + MTX (Pre-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
3.6%TCZ + MTX (Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + Placebo (Post-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence
—TCZ + Placebo (Pre-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence
1.2%TCZ + Placebo (Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence
11.8%
NCT01219933 · Phase 4 · registry result, not featured evidence
8.3%
NCT01163747 · Phase 4 · registry result, not featured evidence · combination
—8 mg/kg
NCT01195272 · Phase 4 · registry result, not featured evidence
5.5%8 mg/kg
NCT01119859 · Phase 4 · registry result, not featured evidence
—
NCT01089023 · Phase 4 · registry result, not featured evidence
—8 mg/kg
NCT01034397 · Phase 4 · registry result, not featured evidence
1.5%
NCT00996203 · Phase 4 · registry result, not featured evidence
—
NCT02010216 · Phase 4 · registry result, not featured evidence
—8 mg/kg
NCT01010503 · Phase 4 · registry result, not featured evidence
9.8%
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
0%Tocilizumab Monotherapy
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
0.7%Tocilizumab in Combination With Me
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
4.8%
NCT01941940 · Phase 3 · registry result, not featured evidence
4.7%
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
—
NCT01668966 · Phase 3 · registry result, not featured evidence
4.6%Phase 1: Combination Therapy
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
5.4%Phase 1: Tocilizumab Monotherapy
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
6.5%TCZ - All Participants
NCT02001987 · Phase 3 · registry result, not featured evidence
—TCZ MONO - All Participants
NCT02001987 · Phase 3 · registry result, not featured evidence
9.1%
NCT01734993 · Phase 3 · registry result, not featured evidence
—
NCT01951170 · Phase 3 · registry result, not featured evidence
—
NCT01655381 · Phase 3 · registry result, not featured evidence
5%
NCT01988012 · Phase 3 · registry result, not featured evidence
Serious AEs
0%200 mg q2wi
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
show 35 more results
12.5%200 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
0%150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
0%150 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
9.5%150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
7.7%150 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
5.9%100 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
6%100 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
0%100 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
6.9%100 mg qw
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
32.3%Sarilumab + Disease Modifying Anti
NCT01146652 · Phase 3 · combination
24.3%Sarilumab Monotherapy
NCT01146652 · Phase 3 · monotherapy
4.9%200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
17.5%200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—200 mg
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
5.4%200 mg q2w
NCT01709578 · Phase 3
3.3%150 mg q2w
NCT01709578 · Phase 3
11.9%
NCT03449758 · Phase 4 · registry result, not featured evidence
6.5%200 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
3.3%150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
20%200 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
0%150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
6.3%200 mg
NCT02293902 · Phase 3 · registry result, not featured evidence
9.9%150 mg
NCT02293902 · Phase 3 · registry result, not featured evidence
6.9%Sarilumab Rescue
NCT02293902 · Phase 3 · registry result, not featured evidence
5.8%200 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
7.1%200 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
1.8%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
10.1%150 mg
NCT02057250 · Phase 3 · registry result, not featured evidence
—200 mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
3%200mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
—150 mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
1.5%150mg q2w
NCT02121210 · Phase 3 · registry result, not featured evidence
5.9%200 mg q2w
NCT01768572 · Phase 3 · registry result, not featured evidence
2%150 mg q2w
NCT01768572 · Phase 3 · registry result, not featured evidence
—Tocilizumabj
NCT01941095 · Phase 3 · other
show 49 more results
7.6%Tocilizumab + Methotrexate or Othe
NCT01941095 · Phase 3 · combination
6.5%Tocilizumab Monotherapy
NCT01941095 · Phase 3 · monotherapy
8.8%
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
25.3%8 mg/kg
NCT00106535 · Phase 3 · combination
—8 mg/kg
NCT00106535 · Phase 3 · combination
9.7%4 mg/kg
NCT00106535 · Phase 3 · combination
—4 mg/kg
NCT00106535 · Phase 3 · combination
12.7%Tocilizumab IV
NCT01194414 · Phase 3
11.3%Tocilizumab IV Then Tocilizumab SC
NCT01194414 · Phase 3
13.9%Tocilizumab SC
NCT01194414 · Phase 3
12.5%Tocilizumab SC Then Tocilizumab IV
NCT01194414 · Phase 3
8.2%Tocilizumab Pre-filled Syringe
NCT01232569 · Phase 3
10.1%Tocilizumab Pre-filled Syringe to
NCT01232569 · Phase 3
31.1%
NCT01331837 · Phase 4
3.1%Tocilizumab+Prednisone (Constant D
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
5.3%Tocilizumab+Prednisone (Tapering D
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
1.9%
NCT01717859 · Phase 4 · registry result, not featured evidence
15.4%
NCT01715831 · Phase 4 · registry result, not featured evidence
24.8%
NCT01149057 · Phase 4 · registry result, not featured evidence
11.5%TCZ + MTX (Not Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
1.2%TCZ + MTX (Post-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
0%TCZ + MTX (Pre-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
—TCZ + MTX (Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
4.9%TCZ + Placebo (Post-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence
1.2%TCZ + Placebo (Pre-randomization)
NCT01399697 · Phase 4 · registry result, not featured evidence
—TCZ + Placebo (Randomized)
NCT01399697 · Phase 4 · registry result, not featured evidence
—
NCT01219933 · Phase 4 · registry result, not featured evidence
5%
NCT01163747 · Phase 4 · registry result, not featured evidence · combination
19%8 mg/kg
NCT01195272 · Phase 4 · registry result, not featured evidence
11.7%8 mg/kg
NCT01119859 · Phase 4 · registry result, not featured evidence
8.4%
NCT01089023 · Phase 4 · registry result, not featured evidence
5.7%8 mg/kg
NCT01034397 · Phase 4 · registry result, not featured evidence
6%
NCT00996203 · Phase 4 · registry result, not featured evidence
0%
NCT02010216 · Phase 4 · registry result, not featured evidence
9.4%8 mg/kg
NCT01010503 · Phase 4 · registry result, not featured evidence
9%
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
14.3%Tocilizumab Monotherapy
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
5%Tocilizumab in Combination With Me
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
7.5%
NCT01941940 · Phase 3 · registry result, not featured evidence
9.3%
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
9.5%
NCT01668966 · Phase 3 · registry result, not featured evidence
3.1%Phase 1: Combination Therapy
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
4.1%Phase 1: Tocilizumab Monotherapy
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
11.5%TCZ - All Participants
NCT02001987 · Phase 3 · registry result, not featured evidence
11.6%TCZ MONO - All Participants
NCT02001987 · Phase 3 · registry result, not featured evidence
18.2%
NCT01734993 · Phase 3 · registry result, not featured evidence
5.8%
NCT01951170 · Phase 3 · registry result, not featured evidence
6.7%
NCT01655381 · Phase 3 · registry result, not featured evidence
6%
NCT01988012 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
200 mg q2wi
neutropenia 19.6% (placebo 0%)
upper respiratory tract infection 5.9% (placebo 3.9%)
accidental overdose 3.9% (placebo 9.8%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
show 32 more results
200 mg q2w
neutropenia 14.9% (placebo 0%)
upper respiratory tract infection 9.5% (placebo 3.9%)
alanine aminotransferase increased 8.1% (placebo 0%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
150 mg q2w
accidental overdose 5.8% (placebo 9.8%)
alanine aminotransferase increased 5.8% (placebo 0%)
nasopharyngitis 3.8% (placebo 5.9%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
150 mg qw
neutropenia 10% (placebo 0%)
accidental overdose 6% (placebo 9.8%)
rheumatoid arthritis 6% (placebo 2%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
150 mg q2w
neutropenia 9.7% (placebo 0%)
alanine aminotransferase increased 8.4% (placebo 0%)
upper respiratory tract infection 8.4% (placebo 3.9%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
150 mg qw
injection site erythema 11.5% (placebo 0%)
hypertension 7.7% (placebo 2%)
neutropenia 7.7% (placebo 0%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
100 mg q2w
hypertension 3.9% (placebo 2%)
nasopharyngitis 3.9% (placebo 5.9%)
accidental overdose 2% (placebo 9.8%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
100 mg qw
neutropenia 12% (placebo 0%)
urinary tract infection 6% (placebo 2%)
accidental overdose 4% (placebo 9.8%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
100 mg q2w
accidental overdose 10.3% (placebo 9.8%)
hypertension 6.9% (placebo 2%)
neutropenia 3.4% (placebo 0%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
100 mg qw
accidental overdose 6.9% (placebo 9.8%)
rheumatoid arthritis 6.9% (placebo 2%)
hypertension 3.4% (placebo 2%)
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
neutropenia 18.2%
accidental overdose 17.3%
upper respiratory tract infection 15.9%
NCT01146652 · Phase 3 · combination
accidental overdose 18%
neutropenia 16.2%
rheumatoid arthritis 14.4%
NCT01146652 · Phase 3 · monotherapy
200 mg
neutropenia 13.6%
injection site erythema 7.6%
bronchitis 6.5%
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
200 mg
nasopharyngitis 18.8%
neutropenia 18.4%
bronchitis 12.8%
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
200 mg q2w
neutropenia 12% (placebo 1.1%)
urinary tract infection 7.1% (placebo 6.6%)
alanine aminotransferase increased 5.4% (placebo 1.1%)
NCT01709578 · Phase 3
150 mg q2w
neutropenia 12.7% (placebo 1.1%)
hypertriglyceridaemia 6.1% (placebo 1.7%)
injection site erythema 6.1% (placebo 0%)
NCT01709578 · Phase 3
neutropenia 19%
bronchitis 11.9%
nausea 11.9%
NCT03449758 · Phase 4 · registry result, not featured evidence
200 mg q2w
nasopharyngitis 45.2%
injection site erythema 19.4%
hepatic function abnormal 12.9%
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
150 mg q2w
nasopharyngitis 43.3%
rheumatoid arthritis 13.3%
oropharyngeal pain 10%
NCT02373202 · Phase 3 · registry result, not featured evidence · monotherapy
200 mg q2w
nasopharyngitis 33.3%
stomatitis 26.7%
neutropenia 20%
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
150 mg q2w
neutropenia 33.3%
nasopharyngitis 26.7%
contusion 20%
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
200 mg
nasopharyngitis 28.8% (placebo 14.8%)
neutropenia 11.3% (placebo 0%)
stomatitis 10% (placebo 3.7%)
NCT02293902 · Phase 3 · registry result, not featured evidence
150 mg
nasopharyngitis 33.3% (placebo 14.8%)
neutropenia 12.3% (placebo 0%)
hepatic function abnormal 9.9% (placebo 4.9%)
NCT02293902 · Phase 3 · registry result, not featured evidence
nasopharyngitis 32.8% (placebo 14.8%)
stomatitis 12.1% (placebo 3.7%)
neutropenia 10.3% (placebo 0%)
NCT02293902 · Phase 3 · registry result, not featured evidence
200 mg
neutropenia 11.5%
alanine aminotransferase increased 9.6%
injection site erythema 7.7%
NCT02057250 · Phase 3 · registry result, not featured evidence
200 mg
injection site erythema 7.1%
injection site pruritus 7.1%
neutropenia 7.1%
NCT02057250 · Phase 3 · registry result, not featured evidence
150 mg
neutropenia 17.9%
pharyngitis 8.9%
bronchitis 7.1%
NCT02057250 · Phase 3 · registry result, not featured evidence
150 mg
neutropenia 17%
sinusitis 5.7%
injection site erythema 3.8%
NCT02057250 · Phase 3 · registry result, not featured evidence
150 mg
upper respiratory tract infection 13.3%
neutropenia 6.4%
sinusitis 6.4%
NCT02057250 · Phase 3 · registry result, not featured evidence
200mg q2w
neutropenia 16.4%
hypertension 6%
upper respiratory tract infection 6%
NCT02121210 · Phase 3 · registry result, not featured evidence
150mg q2w
neutropenia 12.3%
injection site erythema 7.7%
upper respiratory tract infection 4.6%
NCT02121210 · Phase 3 · registry result, not featured evidence
200 mg q2w
neutropenia 15.7%
injection site erythema 7.8%
accidental overdose 5.9%
NCT01768572 · Phase 3 · registry result, not featured evidence
150 mg q2w
nasopharyngitis 12.2%
neutropenia 12.2%
injection site erythema 8.2%
NCT01768572 · Phase 3 · registry result, not featured evidence
j
alanine aminotransferase increased 19.7%
aspartate aminotransferase increased 13.6%
leukopenia 12.1%
NCT01941095 · Phase 3 · combination
show 43 more results
alanine aminotransferase increased 29%
aspartate aminotransferase increased 25.8%
neutropenia 19.4%
NCT01941095 · Phase 3 · monotherapy
bronchitis 15.8%
cough 12.3%
nasopharyngitis 12.3%
NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
8 mg/kg
upper respiratory tract infection 24.3% (placebo 7.4%)
urinary tract infection 16.1% (placebo 5.1%)
hypertension 13.4% (placebo 3.1%)
NCT00106535 · Phase 3 · combination
4 mg/kg
upper respiratory tract infection 9.2% (placebo 7.4%)
hypertension 5.7% (placebo 3.1%)
urinary tract infection 5.7% (placebo 5.1%)
NCT00106535 · Phase 3 · combination
alanine aminotransferase increased 22.2%
upper respiratory tract infection 20.6%
aspartate aminotransferase increased 15.2%
NCT01194414 · Phase 3
upper respiratory tract infection 17.7%
alanine aminotransferase increased 15.6%
nasopharyngitis 14%
NCT01194414 · Phase 3
alanine aminotransferase increased 29.8%
aspartate aminotransferase increased 21.4%
upper respiratory tract infection 19.3%
NCT01194414 · Phase 3
upper respiratory tract infection 16.7%
alanine aminotransferase increased 14.6%
nasopharyngitis 14.6%
NCT01194414 · Phase 3
alanine aminotransferase increased 15.3% (placebo 6%)
upper respiratory tract infection 11.9% (placebo 6.4%)
aspartate aminotransferase increased 9.2% (placebo 4.6%)
NCT01232569 · Phase 3
alanine aminotransferase increased 14.3% (placebo 6%)
upper respiratory tract infection 12.5% (placebo 6.4%)
nasopharyngitis 9.5% (placebo 2.3%)
NCT01232569 · Phase 3
bronchitis 15.9%
upper respiratory tract infection 15.8%
nasopharyngitis 15.5%
NCT01331837 · Phase 4
nasopharyngitis 7%
diarrhoea 3.9%
alanine aminotransferase increased 2.3%
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 9.9%
alanine aminotransferase increased 6.9%
aspartate aminotransferase increased 6.9%
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
rheumatoid arthritis flare 38.9%
upper respiratory infection 38.9%
hypercholesterolemia 31.5%
NCT01717859 · Phase 4 · registry result, not featured evidence
respiratory tract infection nos 46.2%
musculoskeletal pain 30.8%
urinary tract infection 26.9%
NCT01715831 · Phase 4 · registry result, not featured evidence
alanine aminotransferase/aspartate aminotransferase elevations 32.4%
leukopenia 22.1%
upper respiratory tract infection 17.2%
NCT01149057 · Phase 4 · registry result, not featured evidence
hypertransaminasaemia 15.6%
hypercholesterolaemia 9.4%
leukopenia 7.3%
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
hypertransaminasaemia 9.6%
aphthous stomatitis 0%
hypercholesterolaemia 0%
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
hypertransaminasaemia 14.5%
aphthous stomatitis 3.6%
urinary tract infection 3.6%
NCT01399697 · Phase 4 · registry result, not featured evidence · combination
hypertransaminasaemia 4.9%
aphthous stomatitis 0%
hypercholesterolaemia 0%
NCT01399697 · Phase 4 · registry result, not featured evidence
hypertransaminasaemia 12.2%
aphthous stomatitis 7.3%
hypercholesterolaemia 7.3%
NCT01399697 · Phase 4 · registry result, not featured evidence
sinusitis 8.3%
headache 6.7%
nausea 6.7%
NCT01163747 · Phase 4 · registry result, not featured evidence · combination
8 mg/kg
rheumatoid arthritis 47.6%
lower respiratory tract infection 42.9%
nasopharyngitis 38.1%
NCT01195272 · Phase 4 · registry result, not featured evidence
8 mg/kg
upper respiratory tract infection 11.1%
nasopharyngitis 10.5%
hypertension 8%
NCT01119859 · Phase 4 · registry result, not featured evidence
investigations 30.5%
blood and lymphatic system disorders 7.4%
infections and infestations 7.4%
NCT01089023 · Phase 4 · registry result, not featured evidence
8 mg/kg
urinary tract infection 11.4% (placebo 10%)
hypercholesterolemia 8.6% (placebo 10%)
elevated alt 5.7% (placebo 0%)
NCT01034397 · Phase 4 · registry result, not featured evidence
alanine aminotransferase increased 4.5%
transaminases increased 4%
respiratory tract infection 3%
NCT00996203 · Phase 4 · registry result, not featured evidence
drowsiness 8.7%
NCT02010216 · Phase 4 · registry result, not featured evidence
8 mg/kg
acute bronchitis 9.4%
leucopenia+lymphopenia 9.4%
hepatopathy 6.3%
NCT01010503 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15%
hypertension 12.8%
nausea 8.3%
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
lower respiratory tract infection 28.6%
nasopharyngitis 23.8%
urinary tract infection 23.8%
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
nasopharyngitis 23.6%
diarrhoea 22.9%
alanine aminotransferase increased 22.1%
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
influenza 10.1%
cough 7%
bronchitis 6.6%
NCT01941940 · Phase 3 · registry result, not featured evidence
nasopharyngitis 23.3%
fatigue 12%
nausea 12%
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 42.9%
dyslipidaemia 23.8%
upper respiratory tract infection 19%
NCT01668966 · Phase 3 · registry result, not featured evidence
transaminases increased 11.3%
upper respiratory tract infection 7%
urinary tract infection 7%
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
injection site erythema 8.1%
urinary tract infection 8.1%
back pain 5.4%
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
rheumatoid arthritis 13.7%
bronchitis 11.5%
rhinitis 9.4%
NCT02001987 · Phase 3 · registry result, not featured evidence
rheumatoid arthritis 18.6%
bronchitis 16.3%
ear infection 11.6%
NCT02001987 · Phase 3 · registry result, not featured evidence
bronchitis 45.5%
arthralgia 36.4%
urinary tract infection 27.3%
NCT01734993 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 28.8%
rheumatoid arthritis 21.2%
neutropenia 11.5%
NCT01951170 · Phase 3 · registry result, not featured evidence
bronchitis 40%
back pain 33.3%
asthenia 26.7%
NCT01655381 · Phase 3 · registry result, not featured evidence
neutropenia 12%
hepatic enzyme increased 11%
leukopenia 11%
NCT01988012 · Phase 3 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 52 weeks versus 24 weeks.
  5. eTrial phases differ: Phase 3 versus Phase 4.
  6. fTreatment context differs: monotherapy versus combination.
  7. gTrial phases differ: Phase 4 versus Phase 3.
  8. hAssessment timepoints differ: 192 weeks versus 24 weeks.
  9. iPopulation comparability has not been reviewed for 23 of these studies.
  10. jPopulation comparability has not been reviewed for 49 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Sarilumab

Major Clinical 14.8% (n=399) vs 3% (n=398) placebo @ 52wk200 mg q2w
responder rate · % of participants
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
show 1 more result
12.8% (n=400) vs 3% (n=398) placebo @ 52wk150 mg q2w
NCT01061736 · Phase 2/3 · combination · Rheumatoid Arthritis · phase 2/3
DAS28-CRP -2.47 score @ 52wk200 mg q2w
absolute change · score
No placebo or comparator arm
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
show 50 more results
-2.9 score @ 52wk150 mg q2w
NCT02373202 · Phase 3 · registry result, not featured evidence · combination
-2.5 score @ 0wk
NCT01146652 · Phase 3 · combination
-2.99 score @ 0wk
NCT01146652 · Phase 3 · monotherapy
-2.98 score @ 4wk
NCT01146652 · Phase 3 · combination
-3.18 score @ 4wk
NCT01146652 · Phase 3 · monotherapy
-3.12 score @ 8wk
NCT01146652 · Phase 3 · combination
-3.21 score @ 8wk
NCT01146652 · Phase 3 · monotherapy
-3.19 score @ 12wk
NCT01146652 · Phase 3 · combination
-3.28 score @ 12wk
NCT01146652 · Phase 3 · monotherapy
-3.28 score @ 24wk
NCT01146652 · Phase 3 · combination
-3.43 score @ 24wk
NCT01146652 · Phase 3 · monotherapy
-3.31 score @ 36wk
NCT01146652 · Phase 3 · combination
-3.35 score @ 36wk
NCT01146652 · Phase 3 · monotherapy
-3.35 score @ 48wk
NCT01146652 · Phase 3 · combination
-3.36 score @ 48wk
NCT01146652 · Phase 3 · monotherapy
-3.41 score @ 60wk
NCT01146652 · Phase 3 · combination
-3.5 score @ 60wk
NCT01146652 · Phase 3 · monotherapy
-3.41 score @ 72wk
NCT01146652 · Phase 3 · combination
-3.61 score @ 72wk
NCT01146652 · Phase 3 · monotherapy
-3.4 score @ 84wk
NCT01146652 · Phase 3 · combination
-3.7 score @ 84wk
NCT01146652 · Phase 3 · monotherapy
-3.46 score @ 96wk
NCT01146652 · Phase 3 · combination
-3.59 score @ 96wk
NCT01146652 · Phase 3 · monotherapy
-3.49 score @ 120wk
NCT01146652 · Phase 3 · combination
-3.72 score @ 120wk
NCT01146652 · Phase 3 · monotherapy
-3.51 score @ 144wk
NCT01146652 · Phase 3 · combination
-3.79 score @ 144wk
NCT01146652 · Phase 3 · monotherapy
-3.52 score @ 168wk
NCT01146652 · Phase 3 · combination
-3.66 score @ 168wk
NCT01146652 · Phase 3 · monotherapy
-3.55 score @ 192wk
NCT01146652 · Phase 3 · combination
-3.61 score @ 192wk
NCT01146652 · Phase 3 · monotherapy
-3.59 score @ 216wk
NCT01146652 · Phase 3 · combination
-3.71 score @ 216wk
NCT01146652 · Phase 3 · monotherapy
-3.57 score @ 240wk
NCT01146652 · Phase 3 · combination
-3.9 score @ 240wk
NCT01146652 · Phase 3 · monotherapy
-3.64 score @ 264wk
NCT01146652 · Phase 3 · combination
-3.92 score @ 264wk
NCT01146652 · Phase 3 · monotherapy
-3.8 score @ 288wk
NCT01146652 · Phase 3 · combination
-4.38 score @ 288wk
NCT01146652 · Phase 3 · monotherapy
-3.86 score @ 312wk
NCT01146652 · Phase 3 · combination
-5.62 score @ 312wk
NCT01146652 · Phase 3 · monotherapy
-3.86 score @ 336wk
NCT01146652 · Phase 3 · combination
-3.93 score @ 360wk
NCT01146652 · Phase 3 · combination
-3.99 score @ 384wk
NCT01146652 · Phase 3 · combination
-3.85 score @ 408wk
NCT01146652 · Phase 3 · combination
-4.11 score @ 432wk
NCT01146652 · Phase 3 · combination
-4.01 score @ 456wk
NCT01146652 · Phase 3 · combination
-3.69 score @ 480wk
NCT01146652 · Phase 3 · combination
-3.76 score @ 504wk
NCT01146652 · Phase 3 · combination
-3.76 score @ 516wk
NCT01146652 · Phase 3 · combination
mTSS no Progression 51.9% (n=889) @ 0wk
responder rate · % of participants
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 6 more results
51.2% (n=889) @ 48wk
NCT01146652 · Phase 3 · combination
46.6% (n=796) @ 48wk
NCT01146652 · Phase 3 · combination
44.2% (n=796) @ 96wk
NCT01146652 · Phase 3 · combination
48.6% (n=732) @ 96wk
NCT01146652 · Phase 3 · combination
46% (n=732) @ 144wk
NCT01146652 · Phase 3 · combination
41.8% (n=732) @ 192wk
NCT01146652 · Phase 3 · combination
TJC -16.67 joints @ 0wk
absolute change · joints
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 48 more results
-19.86 joints @ 0wk
NCT01146652 · Phase 3 · monotherapy
-18.97 joints @ 4wk
NCT01146652 · Phase 3 · combination
-20.13 joints @ 4wk
NCT01146652 · Phase 3 · monotherapy
-19.72 joints @ 8wk
NCT01146652 · Phase 3 · combination
-20.09 joints @ 8wk
NCT01146652 · Phase 3 · monotherapy
-20.2 joints @ 12wk
NCT01146652 · Phase 3 · combination
-20.05 joints @ 12wk
NCT01146652 · Phase 3 · monotherapy
-20.67 joints @ 24wk
NCT01146652 · Phase 3 · combination
-21.19 joints @ 24wk
NCT01146652 · Phase 3 · monotherapy
-20.68 joints @ 36wk
NCT01146652 · Phase 3 · combination
-20.6 joints @ 36wk
NCT01146652 · Phase 3 · monotherapy
-20.95 joints @ 48wk
NCT01146652 · Phase 3 · combination
-20.27 joints @ 48wk
NCT01146652 · Phase 3 · monotherapy
-21.29 joints @ 60wk
NCT01146652 · Phase 3 · combination
-20.95 joints @ 60wk
NCT01146652 · Phase 3 · monotherapy
-21.41 joints @ 72wk
NCT01146652 · Phase 3 · combination
-21.67 joints @ 72wk
NCT01146652 · Phase 3 · monotherapy
-21.53 joints @ 84wk
NCT01146652 · Phase 3 · combination
-21.36 joints @ 84wk
NCT01146652 · Phase 3 · monotherapy
-21.65 joints @ 96wk
NCT01146652 · Phase 3 · combination
-20.89 joints @ 96wk
NCT01146652 · Phase 3 · monotherapy
-21.92 joints @ 120wk
NCT01146652 · Phase 3 · combination
-20.18 joints @ 120wk
NCT01146652 · Phase 3 · monotherapy
-22.13 joints @ 144wk
NCT01146652 · Phase 3 · combination
-22.52 joints @ 144wk
NCT01146652 · Phase 3 · monotherapy
-22.35 joints @ 168wk
NCT01146652 · Phase 3 · combination
-22.42 joints @ 168wk
NCT01146652 · Phase 3 · monotherapy
-22.62 joints @ 192wk
NCT01146652 · Phase 3 · combination
-21.83 joints @ 192wk
NCT01146652 · Phase 3 · monotherapy
-22.69 joints @ 216wk
NCT01146652 · Phase 3 · combination
-22.33 joints @ 216wk
NCT01146652 · Phase 3 · monotherapy
-22.89 joints @ 240wk
NCT01146652 · Phase 3 · combination
-23.07 joints @ 240wk
NCT01146652 · Phase 3 · monotherapy
-23.09 joints @ 264wk
NCT01146652 · Phase 3 · combination
-23.66 joints @ 264wk
NCT01146652 · Phase 3 · monotherapy
-22.59 joints @ 288wk
NCT01146652 · Phase 3 · combination
-28.95 joints @ 288wk
NCT01146652 · Phase 3 · monotherapy
-23.47 joints @ 312wk
NCT01146652 · Phase 3 · combination
-43.71 joints @ 312wk
NCT01146652 · Phase 3 · monotherapy
-23.37 joints @ 336wk
NCT01146652 · Phase 3 · combination
-24.12 joints @ 360wk
NCT01146652 · Phase 3 · combination
-24.73 joints @ 384wk
NCT01146652 · Phase 3 · combination
-24.58 joints @ 408wk
NCT01146652 · Phase 3 · combination
-25.33 joints @ 432wk
NCT01146652 · Phase 3 · combination
-24.21 joints @ 456wk
NCT01146652 · Phase 3 · combination
-21.23 joints @ 480wk
NCT01146652 · Phase 3 · combination
-23.62 joints @ 504wk
NCT01146652 · Phase 3 · combination
-24 joints @ 516wk
NCT01146652 · Phase 3 · combination
Swollen Joint Count -11.36 joints @ 0wk
absolute change · joints
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 51 more results
-14.06 joints @ 0wk
NCT01146652 · Phase 3 · monotherapy
-12.81 joints @ 4wk
NCT01146652 · Phase 3 · combination
-14.55 joints @ 4wk
NCT01146652 · Phase 3 · monotherapy
-13.43 joints @ 8wk
NCT01146652 · Phase 3 · combination
-14.6 joints @ 8wk
NCT01146652 · Phase 3 · monotherapy
-13.77 joints @ 12wk
NCT01146652 · Phase 3 · combination
-14.58 joints @ 12wk
NCT01146652 · Phase 3 · monotherapy
-14.28 joints @ 24wk
NCT01146652 · Phase 3 · combination
-14.83 joints @ 24wk
NCT01146652 · Phase 3 · monotherapy
-14.37 joints @ 36wk
NCT01146652 · Phase 3 · combination
-14.51 joints @ 36wk
NCT01146652 · Phase 3 · monotherapy
-14.53 joints @ 48wk
NCT01146652 · Phase 3 · combination
-14.96 joints @ 48wk
NCT01146652 · Phase 3 · monotherapy
-14.75 joints @ 60wk
NCT01146652 · Phase 3 · combination
-15.54 joints @ 60wk
NCT01146652 · Phase 3 · monotherapy
-14.76 joints @ 72wk
NCT01146652 · Phase 3 · combination
-15.43 joints @ 72wk
NCT01146652 · Phase 3 · monotherapy
-14.84 joints @ 84wk
NCT01146652 · Phase 3 · combination
-15.83 joints @ 84wk
NCT01146652 · Phase 3 · monotherapy
-15.03 joints @ 96wk
NCT01146652 · Phase 3 · combination
-15.51 joints @ 96wk
NCT01146652 · Phase 3 · monotherapy
-15.09 joints @ 120wk
NCT01146652 · Phase 3 · combination
-15.77 joints @ 120wk
NCT01146652 · Phase 3 · monotherapy
-15.18 joints @ 144wk
NCT01146652 · Phase 3 · combination
-15.9 joints @ 144wk
NCT01146652 · Phase 3 · monotherapy
-15.16 joints @ 168wk
NCT01146652 · Phase 3 · combination
-15.47 joints @ 168wk
NCT01146652 · Phase 3 · monotherapy
-15.26 joints @ 192wk
NCT01146652 · Phase 3 · combination
-15.01 joints @ 192wk
NCT01146652 · Phase 3 · monotherapy
-15.25 joints @ 216wk
NCT01146652 · Phase 3 · combination
-15.72 joints @ 216wk
NCT01146652 · Phase 3 · monotherapy
-15.43 joints @ 240wk
NCT01146652 · Phase 3 · combination
-15.59 joints @ 240wk
NCT01146652 · Phase 3 · monotherapy
-15.5 joints @ 264wk
NCT01146652 · Phase 3 · combination
-16.59 joints @ 264wk
NCT01146652 · Phase 3 · monotherapy
-14.67 joints @ 288wk
NCT01146652 · Phase 3 · combination
-18.65 joints @ 288wk
NCT01146652 · Phase 3 · monotherapy
-15.38 joints @ 312wk
NCT01146652 · Phase 3 · combination
-23.57 joints @ 312wk
NCT01146652 · Phase 3 · monotherapy
-15.51 joints @ 336wk
NCT01146652 · Phase 3 · combination
-15.96 joints @ 360wk
NCT01146652 · Phase 3 · combination
-16.42 joints @ 384wk
NCT01146652 · Phase 3 · combination
-16.3 joints @ 408wk
NCT01146652 · Phase 3 · combination
-16.62 joints @ 432wk
NCT01146652 · Phase 3 · combination
-15.64 joints @ 456wk
NCT01146652 · Phase 3 · combination
-15.43 joints @ 480wk
NCT01146652 · Phase 3 · combination
-16.21 joints @ 504wk
NCT01146652 · Phase 3 · combination
-13 joints @ 516wk
NCT01146652 · Phase 3 · combination
-3.9 joints @ 4wk
NCT03449758 · Phase 4 · registry result, not featured evidence
-4.1 joints @ 12wk
NCT03449758 · Phase 4 · registry result, not featured evidence
-4.7 joints @ 24wk
NCT03449758 · Phase 4 · registry result, not featured evidence
SF-36 PCS 7.95 score @ 0wk
absolute change · score
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 15 more results
8.84 score @ 12wk
NCT01146652 · Phase 3 · combination
9.25 score @ 24wk
NCT01146652 · Phase 3 · combination
9.72 score @ 36wk
NCT01146652 · Phase 3 · combination
9.43 score @ 48wk
NCT01146652 · Phase 3 · combination
9.64 score @ 60wk
NCT01146652 · Phase 3 · combination
9.62 score @ 72wk
NCT01146652 · Phase 3 · combination
9.95 score @ 84wk
NCT01146652 · Phase 3 · combination
9.9 score @ 96wk
NCT01146652 · Phase 3 · combination
10.18 score @ 120wk
NCT01146652 · Phase 3 · combination
10.15 score @ 144wk
NCT01146652 · Phase 3 · combination
10.24 score @ 168wk
NCT01146652 · Phase 3 · combination
10.34 score @ 192wk
NCT01146652 · Phase 3 · combination
10.15 score @ 216wk
NCT01146652 · Phase 3 · combination
10.38 score @ 240wk
NCT01146652 · Phase 3 · combination
10.32 score @ 264wk
NCT01146652 · Phase 3 · combination
SF-36 MCS 6.43 score @ 0wk
absolute change · score
No placebo or comparator arm
NCT01146652 · Phase 3 · combination
show 15 more results
7.15 score @ 12wk
NCT01146652 · Phase 3 · combination
7.43 score @ 24wk
NCT01146652 · Phase 3 · combination
7.2 score @ 36wk
NCT01146652 · Phase 3 · combination
7.48 score @ 48wk
NCT01146652 · Phase 3 · combination
7.43 score @ 60wk
NCT01146652 · Phase 3 · combination
7.25 score @ 72wk
NCT01146652 · Phase 3 · combination
7.29 score @ 84wk
NCT01146652 · Phase 3 · combination
7.47 score @ 96wk
NCT01146652 · Phase 3 · combination
7.69 score @ 120wk
NCT01146652 · Phase 3 · combination
7.22 score @ 144wk
NCT01146652 · Phase 3 · combination
7.29 score @ 168wk
NCT01146652 · Phase 3 · combination
7.1 score @ 192wk
NCT01146652 · Phase 3 · combination
7.2 score @ 216wk
NCT01146652 · Phase 3 · combination
7.23 score @ 240wk
NCT01146652 · Phase 3 · combination
7.32 score @ 264wk
NCT01146652 · Phase 3 · combination
DAS28-ESR Remission 26.6% (n=184) vs 7% (n=185) Adalimumab @ 24wk200 mg
responder rate · % of participants
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
SF-36 PCS 8.74 vs 6.09 Adalimumab score @ 24wk200 mg
absolute change · score
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 2 more results
8.48 vs 4.4 placebo score @ 24wk200 mg q2w
NCT01709578 · Phase 3
7.65 vs 4.4 placebo score @ 24wk150 mg q2w
NCT01709578 · Phase 3
SF-36 MCS 7.86 vs 6.83 Adalimumab score @ 24wk200 mg
absolute change · score
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 2 more results
6.76 vs 4.74 placebo score @ 24wk200 mg q2w
NCT01709578 · Phase 3
6.26 vs 4.74 placebo score @ 24wk150 mg q2w
NCT01709578 · Phase 3
DAS28-CRP -2.86 vs -1.97 Adalimumab score @ 24wk200 mg
absolute change · score
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
-2.82 vs -1.38 placebo score @ 24wk200 mg q2w
NCT01709578 · Phase 3
-2.45 vs -0.97 placebo score @ 12wk200 mg q2w
NCT01709578 · Phase 3
-2.35 vs -1.38 placebo score @ 24wk150 mg q2w
NCT01709578 · Phase 3
-2.13 vs -0.97 placebo score @ 12wk150 mg q2w
NCT01709578 · Phase 3
DAS28 (CRP) Remission 34.2% (n=184) vs 13.5% (n=185) Adalimumab @ 24wk200 mg
responder rate · % of participants
NCT02332590 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
28.8% (n=184) vs 7.2% (n=181) placebo @ 24wk200 mg q2w
NCT01709578 · Phase 3
17.9% (n=184) vs 3.9% (n=181) placebo @ 12wk200 mg q2w
NCT01709578 · Phase 3
24.9% (n=181) vs 7.2% (n=181) placebo @ 24wk150 mg q2w
NCT01709578 · Phase 3
17.1% (n=181) vs 3.9% (n=181) placebo @ 12wk150 mg q2w
NCT01709578 · Phase 3

+ 23 further endpoints in the CSV export.

tocilizumab

DAS28-ESR Remission 40% (n=80) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT01941095 · Phase 3 · other
show 53 more results
4.8% (n=21) @ 2wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 1 participants as posted
10.7% (n=140) @ 2wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 15 participants as posted
9.5% (n=21) @ 4wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 2 participants as posted
24.3% (n=140) @ 4wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 34 participants as posted
23.8% (n=21) @ 8wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 5 participants as posted
37.9% (n=140) @ 8wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 53 participants as posted
28.6% (n=21) @ 12wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 6 participants as posted
47.1% (n=140) @ 12wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 66 participants as posted
47.6% (n=21) @ 16wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 10 participants as posted
51.4% (n=140) @ 16wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 72 participants as posted
52.4% (n=21) @ 20wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 11 participants as posted
53.6% (n=140) @ 20wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 75 participants as posted
66.7% (n=21) @ 24wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 14 participants as posted
54.3% (n=140) @ 24wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 76 participants as posted
66.7% (n=21) @ 28wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 14 participants as posted
52.1% (n=140) @ 28wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 73 participants as posted
57.1% (n=21) @ 32wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 12 participants as posted
57.1% (n=140) @ 32wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 80 participants as posted
66.7% (n=21) @ 36wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 14 participants as posted
57.1% (n=140) @ 36wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 80 participants as posted
61.9% (n=21) @ 40wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 13 participants as posted
57.9% (n=140) @ 40wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 81 participants as posted
47.6% (n=21) @ 44wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 10 participants as posted
57.1% (n=140) @ 44wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 80 participants as posted
52.4% (n=21) @ 48wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 11 participants as posted
55.7% (n=140) @ 48wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 78 participants as posted
57.1% (n=21) @ 52wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy · converted to % from 12 participants as posted
57.1% (n=140) @ 52wk*
NCT02046603 · Phase 3 · registry result, not featured evidence · combination · converted to % from 80 participants as posted
82.6% (n=23) @ 28wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
90.6% (n=66) @ 28wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
87% (n=23) @ 28wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
83.1% (n=67) @ 28wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
81.8% (n=23) @ 32wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
89.1% (n=66) @ 32wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
78.3% (n=23) @ 32wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
82.1% (n=67) @ 32wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
90.5% (n=23) @ 36wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
76.9% (n=66) @ 36wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
86.4% (n=23) @ 36wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
86.4% (n=67) @ 36wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
85% (n=23) @ 40wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
81.3% (n=66) @ 40wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
77.3% (n=23) @ 40wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
81.8% (n=67) @ 40wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
94.7% (n=23) @ 44wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
87.3% (n=66) @ 44wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
77.3% (n=23) @ 44wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
78.8% (n=67) @ 44wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
100% (n=23) @ 48wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
89.1% (n=66) @ 48wkqw
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
77.3% (n=23) @ 48wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
72.7% (n=67) @ 48wkq2w
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
76.6% (n=52) @ 24wk
NCT01951170 · Phase 3 · registry result, not featured evidence
SDAI -3.41 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT01941095 · Phase 3 · other
show 84 more results
-6.54 score @ 4wk
NCT01941095 · Phase 3 · other
-8.72 score @ 8wk
NCT01941095 · Phase 3 · other
-11.07 score @ 12wk
NCT01941095 · Phase 3 · other
-13.47 score @ 16wk
NCT01941095 · Phase 3 · other
-13.88 score @ 20wk
NCT01941095 · Phase 3 · other
-14.08 score @ 24wk
NCT01941095 · Phase 3 · other
-15.37 score @ 28wk
NCT01941095 · Phase 3 · other
-16.09 score @ 32wk
NCT01941095 · Phase 3 · other
-15.61 score @ 36wk
NCT01941095 · Phase 3 · other
-14.86 score @ 40wk
NCT01941095 · Phase 3 · other
-16.31 score @ 44wk
NCT01941095 · Phase 3 · other
-16.47 score @ 48wk
NCT01941095 · Phase 3 · other
-17.35 score @ 52wk
NCT01941095 · Phase 3 · other
2.511 score @ 24wk
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
0.248 score @ 24wk
NCT02573012 · Phase 4 · registry result, not featured evidence · combination
-15.37 score @ 2wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-20.32 score @ 4wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-25.89 score @ 8wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-26.19 score @ 12wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-29.03 score @ 16wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-28.47 score @ 20wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-28.93 score @ 24wk
NCT02046616 · Phase 3 · registry result, not featured evidence · combination
-9.8 score @ 2wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-6.94 score @ 2wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-12.64 score @ 4wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-13.92 score @ 4wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-19.75 score @ 8wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-17.21 score @ 8wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-14.65 score @ 12wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-20.26 score @ 12wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-19.48 score @ 16wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-21.16 score @ 16wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-23.67 score @ 20wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-20.5 score @ 20wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-24.31 score @ 24wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-23.48 score @ 24wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-24.87 score @ 28wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-23.26 score @ 28wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-22.98 score @ 32wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-24.94 score @ 32wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-26.32 score @ 36wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-24.65 score @ 36wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-27.29 score @ 40wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-25.46 score @ 40wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-27.71 score @ 44wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-26.08 score @ 44wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-26.83 score @ 48wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-26.13 score @ 48wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-27.45 score @ 52wk
NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy
-26.15 score @ 52wk
NCT02046603 · Phase 3 · registry result, not featured evidence · combination
-26.5 score @ 2wk
NCT01941940 · Phase 3 · registry result, not featured evidence
-38.9 score @ 24wk
NCT01941940 · Phase 3 · registry result, not featured evidence
-39.3 score @ 52wk
NCT01941940 · Phase 3 · registry result, not featured evidence
-6.2 score @ 2wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-11.3 score @ 4wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-14.4 score @ 8wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-17.2 score @ 12wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-18.5 score @ 16wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-19.7 score @ 20wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-19.9 score @ 24wk
NCT01987479 · Phase 3 · registry result, not featured evidence · combination
-20.45 score @ 2wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-19.5 score @ 2wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-27.86 score @ 4wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-24.34 score @ 4wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-32.61 score @ 8wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-29.34 score @ 8wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-36.23 score @ 12wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-30.95 score @ 12wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-37.82 score @ 16wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-32.66 score @ 16wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-36.79 score @ 20wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-33.95 score @ 20wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-41.38 score @ 24wk
NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy
-34.8 score @ 24wk
NCT01995201 · Phase 3 · registry result, not featured evidence · combination
-8.54 score @ 2wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-14.23 score @ 4wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-20.2 score @ 8wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-23.09 score @ 12wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-24.31 score @ 16wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-24.41 score @ 20wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-22.45 score @ 24wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-23.29 score @ 24wk
NCT02001987 · Phase 3 · registry result, not featured evidence
-31.6 score @ 24wk
NCT01951170 · Phase 3 · registry result, not featured evidence
-21.41 score @ 24wk
NCT01988012 · Phase 3 · registry result, not featured evidence
TJC28 -1.3 tender joints @ 2wk
absolute change · tender joints
No placebo or comparator arm
NCT01941095 · Phase 3 · other
show 13 more results
-3.26 tender joints @ 4wk
NCT01941095 · Phase 3 · other
-4.97 tender joints @ 8wk
NCT01941095 · Phase 3 · other
-5.82 tender joints @ 12wk
NCT01941095 · Phase 3 · other
-6.39 tender joints @ 16wk
NCT01941095 · Phase 3 · other
-7.03 tender joints @ 20wk
NCT01941095 · Phase 3 · other
-7.72 tender joints @ 24wk
NCT01941095 · Phase 3 · other
-7.91 tender joints @ 28wk
NCT01941095 · Phase 3 · other
-8.38 tender joints @ 32wk
NCT01941095 · Phase 3 · other
-8.28 tender joints @ 36wk
NCT01941095 · Phase 3 · other
-8.22 tender joints @ 40wk
NCT01941095 · Phase 3 · other
-8.63 tender joints @ 44wk
NCT01941095 · Phase 3 · other
-8.26 tender joints @ 48wk
NCT01941095 · Phase 3 · other
-8.75 tender joints @ 52wk
NCT01941095 · Phase 3 · other
SJC28 -1.82 swollen joints @ 2wk
absolute change · swollen joints
No placebo or comparator arm
NCT01941095 · Phase 3 · other
show 13 more results
-3.08 swollen joints @ 4wk
NCT01941095 · Phase 3 · other
-4.71 swollen joints @ 8wk
NCT01941095 · Phase 3 · other
-5.24 swollen joints @ 12wk
NCT01941095 · Phase 3 · other
-5.79 swollen joints @ 16wk
NCT01941095 · Phase 3 · other
-6.06 swollen joints @ 20wk
NCT01941095 · Phase 3 · other
-6.6 swollen joints @ 24wk
NCT01941095 · Phase 3 · other
-6.65 swollen joints @ 28wk
NCT01941095 · Phase 3 · other
-6.73 swollen joints @ 32wk
NCT01941095 · Phase 3 · other
-6.76 swollen joints @ 36wk
NCT01941095 · Phase 3 · other
-6.91 swollen joints @ 40wk
NCT01941095 · Phase 3 · other
-6.82 swollen joints @ 44wk
NCT01941095 · Phase 3 · other
-6.63 swollen joints @ 48wk
NCT01941095 · Phase 3 · other
-6.98 swollen joints @ 52wk
NCT01941095 · Phase 3 · other
Corticosteroid Dose Reduction 48.6% (n=37) @ 52wk
responder rate · % of participants
No placebo or comparator arm
NCT01941095 · Phase 3 · other
Swollen Joint Count -9 vs -2.9 placebo count @ 24wk8 mg/kg
absolute change · count
NCT00106535 · Phase 3 · combination
show 5 more results
-10.2 vs -2.5 placebo count @ 52wk8 mg/kg
NCT00106535 · Phase 3 · combination
-11.3 vs -3.5 placebo count @ 104wk8 mg/kg
NCT00106535 · Phase 3 · combination
-7.9 vs -2.9 placebo count @ 24wk4 mg/kg
NCT00106535 · Phase 3 · combination
-8 vs -2.5 placebo count @ 52wk4 mg/kg
NCT00106535 · Phase 3 · combination
-9 vs -3.5 placebo count @ 104wk4 mg/kg
NCT00106535 · Phase 3 · combination
Tender Joint Count -14.2 vs -4.8 placebo count @ 24wk8 mg/kg
absolute change · count
NCT00106535 · Phase 3 · combination
show 5 more results
-15.6 vs -4.1 placebo count @ 52wk8 mg/kg
NCT00106535 · Phase 3 · combination
-17.7 vs -5.9 placebo count @ 104wk8 mg/kg
NCT00106535 · Phase 3 · combination
-12.2 vs -4.8 placebo count @ 24wk4 mg/kg
NCT00106535 · Phase 3 · combination
-12.3 vs -4.1 placebo count @ 52wk4 mg/kg
NCT00106535 · Phase 3 · combination
-13.6 vs -5.9 placebo count @ 104wk4 mg/kg
NCT00106535 · Phase 3 · combination
Patient Global VAS -25.2 vs -17.5 placebo mm @ 24wk8 mg/kg
absolute change · mm
NCT00106535 · Phase 3 · combination
show 1 more result
-25.2 vs -17.5 placebo mm @ 24wk4 mg/kg
NCT00106535 · Phase 3 · combination
Physician Global VAS -39.8 vs -29 placebo mm @ 24wk8 mg/kg
absolute change · mm
NCT00106535 · Phase 3 · combination
show 1 more result
-36.1 vs -29 placebo mm @ 24wk4 mg/kg
NCT00106535 · Phase 3 · combination
Pain VAS -3.3 vs -0.3 placebo mm @ 12wk8 mg/kg
absolute change · mm
NCT01034397 · Phase 4 · registry result, not featured evidence
show 3 more results
-3.7 vs -3.4 placebo mm @ 24wk8 mg/kg
NCT01034397 · Phase 4 · registry result, not featured evidence
-21.8 vs -12.5 placebo mm @ 24wk8 mg/kg
NCT00106535 · Phase 3 · combination
-19.5 vs -12.5 placebo mm @ 24wk4 mg/kg
NCT00106535 · Phase 3 · combination
CRP Change -2.0699 vs -0.356 placebo mg @ 24wk8 mg/kg
absolute change · mg
NCT00106535 · Phase 3 · combination
show 1 more result
-0.9558 vs -0.356 placebo mg @ 24wk4 mg/kg
NCT00106535 · Phase 3 · combination
ESR Change MM HR -36.8 vs -9.5 placebo per hour @ 24wk8 mg/kg
absolute change · per hour
NCT00106535 · Phase 3 · combination
show 1 more result
-21.8 vs -9.5 placebo per hour @ 24wk4 mg/kg
NCT00106535 · Phase 3 · combination

+ 573 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Sarilumab's landscape · tocilizumab's landscape